Quick context
NAD+
并非肽类，而是内源性辅酶；健康及抗衰宣称不等于获批疗效。
This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.
Back to all 64 profiles
No uniform peptide protocol并非肽类药物
Community protocol · NAD+
NAD+: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: Nicotinamide adenine dinucleotide · NAD
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
No uniform peptide protocol
This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.
Amount status
A blanket amount is not meaningful without diagnosis, dosage form, concentration or defined composition.
Profile evidence level: early_human.
Timing
Timing, where relevant, follows the actual product label or professional procedure rather than a peptide schedule.
No individual recommendation.
Cycle/duration
A community cycle is not meaningfully defined for this entry.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
No generic calculator
Reconstitution is not generally applicable to this substance or product class. Form, concentration and handling must come from the exact authentic product and its official labelling.
Reconstitution is not generally applicable to this substance or product class. Form, concentration and handling must come from the exact authentic product and its official labelling.
Mechanism and research questions
Endogenous redox cofactor involved in cellular energy metabolism
NAD+ is classified as “Endogenous redox cofactor involved in cellular energy metabolism”. 并非肽类，而是内源性辅酶；健康及抗衰宣称不等于获批疗效。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
氧化还原辅因子生物学
这涉及在细胞能量和修复反应中充当辅助分子的物质,类似于支持多种不同化学反应的工具。在实验室中测量酶活性和细胞能量标志物。
细胞能量代谢
研究人员研究细胞如何通过线粒体产生和使用能量,类似于测量发动机燃烧燃料的效率。常见测量指标包括细胞模型中的耗氧量和能量输出。
脂肪酸转运
这项研究考察某些物质如何支持脂肪酸进出细胞的运输,类似于将脂肪运送到线粒体进行燃烧的快递服务。在实验室和动物模型中测量脂肪代谢标志物。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
生物黑客与长寿论坛
用户比较自行组合的肽方案,以期影响衰老过程或能量水平,常常依据血液检测或主观幸福感量表。个人自我实验和营销承诺无法取代对照的长期人体研究。
抗衰老论坛
这里比较生长轴、线粒体和皮肤相关肽的组合方案,目的是影响可见或可感知的衰老迹象,通常经过多年个人记录。关于延缓衰老的轶事和商家广告并非科学证据。
精力与疲劳轶事
人们报告在使用线粒体肽或维生素注射后主观感受到的精力提升,通常基于个人每日精力评分。这类印象极易受安慰剂效应影响。
Adverse effects and risk boundaries
- 风险尤其取决于实际成分、剂型、浓度、辅料及医学理由。维生素、辅因子和稀释剂同样可能产生不良反应或相互作用。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 过敏、肝肾疾病、妊娠、相关药物，以及缺乏诊断或产品身份信息，均须在使用前澄清。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 监测应服从具体医学目的，例如确认缺乏、器官功能或耐受性。笼统的肽类化验组合没有意义。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
早期人体数据
健康和抗衰老方面的说法并不等同于经批准的疗效。
Published evidence
已有一些早期、通常规模较小的人体研究或观察,但尚不能作为可靠的疗效证据。
NAD+不是肽类物质,而是一种内源性氧化还原辅因子,不同于MOTS-c等基于肽的线粒体候选物质。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
并非肽类药物
这不是独立的肽类活性成分；具体产品形式及监管状态需要分别判断。
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourcePubMed: biomedical literature database
- Primary/technical sourceFDA: official drug-label search
- Primary/technical sourceFDA — Ingredients suitable for sterile compounding
- Community referenceNAD+ — Peptide Dosing Protocols